Patent 10208310 was granted and assigned to Exicure, Inc. on February, 2019 by the United States Patent and Trademark Office.
TNFα antisense oligonucleotides are provided herein. Methods of treating TNFα diseases or disorders using the TNFα antisense oligonucleotides and related products are provided.